![coadministered cagrilintide and semaglutide in adults with overweight or obesity PDF] Once-weekly for weight management people obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial Efficacy and safety of co-administered](https://figures.semanticscholar.org/a9800c8f0dc40d6d18a09ab6d2f14e71a42af380/7-Figure2-1.png)
coadministered cagrilintide and semaglutide in adults with overweight or obesity PDF] Once-weekly for weight management people obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial Efficacy and safety of co-administered
Efficacy and safety of co administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine New in the August 14, 2025, issue of NEJM: CagrilintideSemaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) Cagrilintide Semaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial) CagriSema: a novel dual pathway approach to target obesity and its complications Cagrilintide & Semaglutide in Overweight Adults (REDEFINE 1) NEJM Med Journal Club
Pay in 4 interest-free payments of $7.03 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
![coadministered cagrilintide and semaglutide in adults with overweight or obesity PDF] Once-weekly for weight management people obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial Efficacy and safety of co-administered](https://www.thelancet.com/cms/10.1016/S2213-8587(25)00402-4/asset/7d856d37-1b1d-4481-9723-c6f28077488d/main.assets/gr2_lrg.jpg)
![coadministered cagrilintide and semaglutide in adults with overweight or obesity PDF] Once-weekly for weight management people obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial Efficacy and safety of co-administered](https://www.nejm.org/cms/asset/2a0337e5-c78b-4b03-b4ff-55b812225879/nejmdo008112_thumb.jpg)
![coadministered cagrilintide and semaglutide in adults with overweight or obesity PDF] Once-weekly for weight management people obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial Efficacy and safety of co-administered](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3699010274317415701)
![coadministered cagrilintide and semaglutide in adults with overweight or obesity PDF] Once-weekly for weight management people obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial Efficacy and safety of co-administered](https://image.oaes.cc/published/article/6d3a37646798a2d253ab6fdae5ae4ebc/mtod60101-coverimg.jpg)
![coadministered cagrilintide and semaglutide in adults with overweight or obesity PDF] Once-weekly for weight management people obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial Efficacy and safety of co-administered](https://i.ytimg.com/vi/9c6OeOHcevQ/hq720.jpg?sqp=-oaymwEhCK4FEIIDSFryq4qpAxMIARUAAAAAGAElAADIQj0AgKJD&rs=AOn4CLDZIUfSSJe3aW3TklaK3fJ-vgy6dQ)